Pliant Therapeutics Inc. (PLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PLRX POWR Grades
- PLRX scores best on the Growth dimension, with a Growth rank ahead of 72.75% of US stocks.
- The strongest trend for PLRX is in Quality, which has been heading down over the past 178 days.
- PLRX ranks lowest in Stability; there it ranks in the 8th percentile.
PLRX Stock Summary
- With a price/sales ratio of 118.06, PLIANT THERAPEUTICS INC has a higher such ratio than 97.8% of stocks in our set.
- As for revenue growth, note that PLRX's revenue has grown -25.64% over the past 12 months; that beats the revenue growth of merely 6.88% of US companies in our set.
- The volatility of PLIANT THERAPEUTICS INC's share price is greater than that of 93.82% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to PLRX, based on their financial statements, market capitalization, and price volatility, are SQZ, EIGR, IKNA, BPMC, and RXDX.
- Visit PLRX's SEC page to see the company's official filings. To visit the company's web site, go to pliantrx.com.
PLRX Valuation Summary
- PLRX's price/earnings ratio is -9.9; this is 144.39% lower than that of the median Healthcare stock.
- PLRX's price/sales ratio has moved up 97.1 over the prior 28 months.
Below are key valuation metrics over time for PLRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PLRX | 2022-09-09 | 109.9 | 7.3 | -9.9 | -9.8 |
| PLRX | 2022-09-08 | 100.7 | 6.7 | -9.1 | -9.0 |
| PLRX | 2022-09-07 | 99.3 | 6.6 | -8.9 | -8.9 |
| PLRX | 2022-09-06 | 97.8 | 6.5 | -8.8 | -8.7 |
| PLRX | 2022-09-02 | 101.8 | 6.8 | -9.2 | -9.1 |
| PLRX | 2022-09-01 | 100.4 | 6.7 | -9.0 | -9.0 |
PLRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PLRX has a Quality Grade of D, ranking ahead of 14.66% of graded US stocks.
- PLRX's asset turnover comes in at 0.047 -- ranking 325th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PLRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.047 | 1 | -0.360 |
| 2021-03-31 | 0.050 | 1 | -0.363 |
| 2020-12-31 | 0.149 | 1 | -0.245 |
PLRX Price Target
For more insight on analysts targets of PLRX, see our PLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $51.33 | Average Broker Recommendation | 1.38 (Strong Buy) |
PLRX Stock Price Chart Interactive Chart >
PLRX Price/Volume Stats
| Current price | $19.83 | 52-week high | $24.81 |
| Prev. close | $20.53 | 52-week low | $3.96 |
| Day low | $19.03 | Volume | 610,100 |
| Day high | $20.25 | Avg. volume | 844,940 |
| 50-day MA | $19.95 | Dividend yield | N/A |
| 200-day MA | $12.01 | Market Cap | 965.36M |
Pliant Therapeutics Inc. (PLRX) Company Bio
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Latest PLRX News From Around the Web
Below are the latest news stories about PLIANT THERAPEUTICS INC that investors may wish to consider to help them evaluate PLRX as an investment opportunity.
Harvard University’s Latest Portfolio: 10 Best Biotech Stock PicksIn this article, we will look at Harvard University’s latest stock portfolio and list its 10 best biotech stock picks. If you want to explore more biotech stocks that make up the top holdings of Harvard Management, you can also take a look at Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks. Harvard Management […] |
Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of DirectorsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately. “I would like to extend a warm welcome to Kate whose global clinical development and strategic leadership experience, including her training as a pulmonologist, |
Stock Market: Dow Jones Up 350 Points; Egg Stock Breaks OutThe major stock market indexes held gains into the early afternoon on Friday, and are near the highs of the day. The Dow Jones Industrial Average is up over 350 points in afternoon trading. The Nasdaq rallied 2.1%, leading the indexes. The S&P 500 gained 1.5%. The Dow Jones Industrial Average added 1.1%. Small caps held up strong, with the... |
Emergent (EBS) Initiates Study on Lassa Virus Vaccine CandidateEmergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever. |
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year. |
PLRX Price Returns
| 1-mo | 4.31% |
| 3-mo | 126.63% |
| 6-mo | 157.53% |
| 1-year | 12.16% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 46.89% |
| 2021 | -40.58% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...